title: Effects of acepromazine maleate on platelet function assessed by use of adenosine diphosphate activated- and arachidonic acid- activated modified thromboelastography in healthy dogs.
abstract: OBJECTIVE
  To evaluate the effect of acepromazine maleate administered IV on platelet function assessed in healthy dogs by use of a modified thromboelastography assay.
  
  
  METHODS
  6 healthy adult mixed-breed dogs.
  
  
  METHODS
  Dogs received each of 3 treatments (saline [0.9% NaCl] solution [1 to 2 mL, IV] and acepromazine maleate [0.05 and 0.1 mg/kg, IV]) in a randomized crossover study with a minimum 3-day washout period between treatments. From each dog, blood samples were collected via jugular venipuncture immediately before and 30 and 240 minutes after administration of each treatment. A modified thromboelastography assay, consisting of citrated kaolin-activated (baseline assessment), reptilase-ADP-activated (ADP-activated), and reptilase-arachidonic acid (AA)-activated (AA-activated) thromboelastography, was performed for each sample. Platelet inhibition was evaluated by assessing the percentage change in maximum amplitude for ADP-activated or AA-activated samples, compared with baseline values. Percentage change in maximum amplitude was analyzed by use of Skillings-Mack tests with significance accepted at a family-wise error rate of P < 0.05 by use of Bonferroni corrections for multiple comparisons.
  
  
  RESULTS
  No significant differences were found in the percentage change of maximum amplitude from baseline for ADP-activated or AA-activated samples among treatments at any time.
  
  
  CONCLUSIONS
  Platelet function in dogs, as assessed by use of a modified thromboelastography assay, was not inhibited by acepromazine at doses of 0.05 or 0.1 mg/kg, IV. This was in contrast to previous reports in which it was suggested that acepromazine may alter platelet function via inhibition of ADP and AA.
authors.affiliation: Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607.
authors.forename: Bobbi J
authors.initials: BJ
authors.lastname: Conner
authors.forename: Rita M
authors.initials: RM
authors.lastname: Hanel
authors.forename: Bernard D
authors.initials: BD
authors.lastname: Hansen
authors.forename: Alison A
authors.initials: AA
authors.lastname: Motsinger-Reif
authors.forename: Makoto
authors.initials: M
authors.lastname: Asakawa
authors.forename: Clifford R
authors.initials: CR
authors.lastname: Swanson
mesh_terms: D000075:Acepromazine / Q000008:administration & dosage / Q000009:adverse effects*; D000244:Adenosine Diphosphate / Q000737:chemistry; D000818:Animals; D016718:Arachidonic Acid / Q000737:chemistry; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology*; D018592:Cross-Over Studies; D004285:Dogs / Q000502:physiology*; D005260:Female; D006487:Hemostasis / Q000187:drug effects*; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000009:adverse effects*; D007275:Injections, Intravenous / Q000662:veterinary; D013916:Thrombelastography / Q000379:methods / Q000662:veterinary
chemical_list: D006993:Hypnotics and Sedatives; D016718:Arachidonic Acid; D000075:Acepromazine; D000244:Adenosine Diphosphate